arformoterol Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 4943 67346-49-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • arformoterol
  • arformoterol tartrate
  • brovana
  • CGP-25827A
the (R,R)-enantiomer of formoterol, is a selective long-acting beta2-adrenergic receptor agonist (beta2-agonist) that has two-fold greater potency than racemic formoterol
  • Molecular weight: 344.41
  • Formula: C19H24N2O4
  • CLOGP: 1.26
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 4
  • TPSA: 90.82
  • ALOGS: -3.92
  • ROTB: 8

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 6, 2006 FDA SUNOVION

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic obstructive pulmonary disease 110.02 40.47 21 78 13773 4625120
Dyspnoea 42.41 40.47 16 83 138969 4499924

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:35523 bronchodilator agent
CHEBI has role CHEBI:49167 anti-asthmatic drug
CHEBI has role CHEBI:35522 beta-adrenergic agonist
FDA MoA N0000009922 Adrenergic beta2-Agonists
FDA EPC N0000175779 beta2-Adrenergic Agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic obstructive lung disease indication 13645005 DOID:3083
Chronic bronchitis indication 63480004 DOID:6132
Pulmonary emphysema indication 87433001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.23 acidic
pKa2 12.47 acidic
pKa3 8.49 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.015MG BASE/2ML BROVANA SUNOVION N021912 Oct. 6, 2006 RX SOLUTION INHALATION 6814953 June 22, 2021 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
EQ 0.015MG BASE/2ML BROVANA SUNOVION N021912 Oct. 6, 2006 RX SOLUTION INHALATION 7348362 June 22, 2021 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
EQ 0.015MG BASE/2ML BROVANA SUNOVION N021912 Oct. 6, 2006 RX SOLUTION INHALATION 7462645 June 22, 2021 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
EQ 0.015MG BASE/2ML BROVANA SUNOVION N021912 Oct. 6, 2006 RX SOLUTION INHALATION 7473710 June 22, 2021 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
EQ 0.015MG BASE/2ML BROVANA SUNOVION N021912 Oct. 6, 2006 RX SOLUTION INHALATION 7541385 June 22, 2021 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST Kd 8.54 SCIENTIFIC LITERATURE DRUG LABEL
Beta-1 adrenergic receptor GPCR AGONIST Kd 6.95 SCIENTIFIC LITERATURE
Beta-3 adrenergic receptor GPCR EC50 7.60 CHEMBL
Beta-2 adrenergic receptor GPCR EC50 9.90 CHEMBL

External reference:

IDSource
D02981 KEGG_DRUG
4026108 VUID
N0000176102 NUI
C0969589 UMLSCUI
5P8VJ2I235 UNII
200815-49-2 SECONDARY_CAS_RN
423317005 SNOMEDCT_US
d05893 MMSL
423347007 SNOMEDCT_US
304962 RXNORM
4026108 VANDF
011766 NDDF
3083544 PUBCHEM_CID
CHEBI:408174 CHEBI
CHEMBL1363 ChEMBL_ID
CHEMBL1200811 ChEMBL_ID
8398 INN_ID
DB01274 DRUGBANK_ID
7479 IUPHAR_LIGAND_ID
CHEMBL1951071 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Brovana HUMAN PRESCRIPTION DRUG LABEL 1 63402-911 SOLUTION 15 ug RESPIRATORY (INHALATION) NDA 20 sections